Jason Roberts, PhD, discusses insights from the BLING III trial, outlining its study design and primary outcomes. His analysis centers on the clinical benefits of continuous infusions while addressing the complexities of antibiotic administration in critical care. This is part 1 of a 2-part series.
Social determinants of health may determine hepatitis C management in the outpatient setting.
Michigan is taking decisive action to support dairy farms affected by the recent outbreak of highly pathogenic avian influenza (HPAI).
FDA approves pneumococcal vaccine V116, Salmonella outbreak linked to a household pet, Japan is currently facing an unprecedented surge in cases of streptococcal toxic shock syndrome, and more this week from Contagion.
Berkeley Heights, NJ-based biopharmaceutical company, CorMedix, is working towards an expanded indication for its DefenCath product, for the prevention of these healthcare-associated infections.
Snapchill coffee products recalled over botulinum toxin concerns.
Understanding the evolving trends in antibiotic resistance among S aureus infections, commonly treated empirically with oral non–β-lactam antibiotics, is essential for guiding effective treatment strategies.
In the last segment of the series, Jones offered his insights for when he considers discharging patients.
In this conversation, Jones discussed concerns around empirical antimicrobial treatment and opportunities to narrow down therapies.
Zero HIV infections from the Phase 3 PURPOSE 1 Trial underscore the importance of innovative HIV prevention strategies across diverse populations.
Findings from the TAC ANRS 12311 trial revealed the success of tailored treatment combinations to the specific genotype of HCV to optimize efficacy and minimize adverse effects.
HCV testing was accepted by more than 80% of patients undergoing mammography and resulted in prompt linkage to care.
With the recent phase 3 data results of the Moderna COVID-19-influenza combination vaccine, the company is working towards regulatory approval and opens the door to possible protection against multiple viruses with less immunizations.
In a 17-year study across 2 Québec hospitals, researchers explored the relationship between antibiotic use and healthcare-associated Clostridioides difficile infections.
Jerry Krishnan, MD, PhD, working with NASEM, examines the multifaceted challenges of defining Long COVID as they introduce a unified definition for this persistent condition.
Study reveals an increase in hospital admissions and the need for advanced respiratory support, particularly among older, healthier children.
The state's attorney general filed the lawsuit against Pfizer for its ‘misleading statements’ about the vaccine.
While the global clinical pipeline for antibacterial treatments displays notable activity, it remains inadequate to address the challenges of antimicrobial resistance.
Tailored for adults, V116's effectiveness covers serotypes linked to 84% of invasive pneumococcal disease in those 50+, outperforming existing vaccines in immune response rates.
Bearded dragon pets carrying this illness and infecting their loving caregivers create a significant public health concern.
Japan is currently facing an unprecedented surge in cases of streptococcal toxic shock syndrome (STSS), a severe and often fatal bacterial infection.
New research offers clues to susceptibility for the antiviral as the CDC updates the public on 2 strains circulating globally.
Experts emphasize prevalent waterborne illnesses and offer preventive advice for the summer season.
In response to evolving data on SARS-CoV-2 strains and rising COVID-19 cases, the FDA advises vaccine manufacturers to explore incorporating the KP2 strain into the upcoming 2024-2025 COVID-19 vaccine formula.
Overcoming “RSV identity crisis,” Moderna announced data for its investigational mRNA-1083 vaccine, BWC0977 effort to target drug-resistant pathogens, and more this week from Contagion.
Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for patient dosing and clinical management strategies associated with concurrent therapy.
Bruce Jones, PharmD, FIDSA, BCPS provides commentary on treating challenging patients with comorbidities such as type 2 diabetes, higher BMI, and advanced age.
Leveraging Evie Ring technology, the collaboration seeks to enhance understanding and develop strategies for managing these illnesses.
A recently published secondary analysis sought to evaluate the risk of MACE in those patients who received one or two doses of the COVID-19 following acute coronary syndromes.
The latest data from the Gonococcal Antimicrobial Susceptibility Surveillance, calls for updated treatment protocols and intensified surveillance measures to address this escalating concern effectively.
